NDLI: Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele

Please wait, while we are loading the content...

Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy

CXCL12/CXCR4 blockade induces multimodal anti-tumor effects thatprolong survival in an immunocompetent mouse model of ovariancancer

GPR56 Regulates VEGF Production and Angiogenesis during Melanoma Progression

Protein Arginine Methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor Programmed Cell Death 4

p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-κB

Year: 2011, Volume: 71, Issue: 15

Year: 2011, Volume: 71, Issue: 14

Year: 2011, Volume: 71, Issue: 13

Year: 2011, Volume: 71, Issue: 12

Year: 2011, Volume: 71, Issue: 11

Year: 2011, Volume: 71, Issue: 10

Year: 2011, Volume: 71, Issue: 9

Year: 2011, Volume: 71, Issue: 8

Year: 2011, Volume: 71, Issue: 7

Year: 2011, Volume: 71, Issue: 6

Year: 2011, Volume: 71, Issue: 5

Year: 2011, Volume: 71, Issue: 4

Year: 2011, Volume: 71, Issue: 3

Year: 2011, Volume: 71, Issue: 2

Year: 2011, Volume: 71, Issue: 1

Year: 2010, Volume: 70

Year: 2009, Volume: 69

Year: 2008, Volume: 68

Year: 2007, Volume: 67

Year: 2006, Volume: 66

Year: 2005, Volume: 65

Year: 2004, Volume: 64

Year: 2003, Volume: 63

Year: 2002, Volume: 62

Year: 2001, Volume: 61

Year: 2000, Volume: 60

Year: 1999, Volume: 59

Year: 1997, Volume: 57

Year: 1996, Volume: 56

Year: 1995, Volume: 55

Year: 1994, Volume: 54

Year: 1989, Volume: 49

Year: 1987, Volume: 47

Year: 1986, Volume: 46

Year: 1985, Volume: 45

Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele

Content Provider	PubMed Central
Author	Virgili, Anna Koptyra, Mateusz Dasgupta, Yashodhara Eliza, Glodkowska-mrowka Stoklosa, Tomasz Nacheva, Elisabeth P. Skorski, Tomasz
Abstract	Chronic myeloid leukemia in chronic phase (CML-CP) cells that harbor oncogenic BCR-ABL1 and normal ABL1 allele often become resistant to the ABL1 kinase inhibitor imatinib. Here we report that loss of the remaining normal ABL1 allele in these tumors, which results from cryptic interstitial deletion in 9q34 in patients who did not achieve a complete cytogenetic remission during treatment, engenders a novel unexpected mechanism of imatinib resistance. BCR-ABL1-positive Abl1−/− leukemia cells were refractory to imatinib as indicated by persistent BCR-ABL1 -mediated tyrosine phosphorylation, lack of BCR-ABL1 protein degradation, increased cell survival and clonogenic activity. Expression of ABL1 kinase, but not a kinase-dead mutant, restored the anti-leukemic effects of imatinib in ABL1-negative CML cells and in BCR-ABL1-positive Abl1−/− murine leukemia cells. The intracellular concentration of imatinib and expression of its transporters were not affected, while proteins involved in BCR-ABL1 degradation were downregulated in Abl1−/− cells. Furthermore, twelve genes associated with imatinib resistance were favorably deregulated in Abl1−/− leukemia. Taken together, our results indicate that loss of the normal ABL1 kinase may serve as a key prognostic factor that exerts major impact on CML treatment outcomes.
Related Links	http://dx.doi.org/10.1158/0008-5472.CAN-11-0068
Starting Page	5381
File Format	PDF
ISSN	15387445
e-ISSN	15387445
Journal	Cancer research
Issue Number	16
Volume Number	71
Language	English
Publisher Date	2011-08-15
Access Restriction	Open
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells

BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

Is Adherence to Imatinib Mesylate Treatment among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients

Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy

Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele

Similar Documents

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells

BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

Is Adherence to Imatinib Mesylate Treatment among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients

Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy

Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele